Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FaR-RMS study in frontline and relapsed rhabdomyosarcoma
NL-OMON59325Phase 2Recruiting
- Sponsor
- University of Birmingham
- Start
- Oct 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, ifosfamide, vincristine, actinomycin D, doxorubicin and 4 more in rhabdomyosarcoma (RMS) (12 arms), sponsored by University of Birmingham. Primary endpoints: Recommended phase 2 dose, Event-free survival and 1 more. Started Oct 2020; status: recruiting.
02
Drugs
irinotecanifosfamidevincristineactinomycin Ddoxorubicin
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NL-OMON59325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59325.